Physician profile
Fadel E Nammour
NPI 1922039684
$3,085.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $997 · 2021: $138 · 2022: $43.73 · 2023: $73.90 · 2024: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115 · Education: $94.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.45 |
| Education | $94.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $1,236.15 | 2019-2020 | |
| Medtronic USA, INC. | $887.08 | 2019-2020 | |
| Gilead Sciences, INC. | $280.44 | 2019-2024 | |
| Janssen Biotech, INC. | $236.36 | 2019-2024 | Stelara |
| Apollo Endosurgery US INC | $87.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.93 | 2019 | |
| Celgene Corporation | $64.92 | 2021-2022 | |
| Abbvie INC. | $38.47 | 2019-2021 | |
| Romark Laboratories, Lc | $35.60 | 2019 | |
| Nestle Healthcare Nutrition INC. | $35.03 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $30.89 | 2023 | Bylvay |
| Daiichi Sankyo INC. | $27.26 | 2019 | |
| Allergan, INC. | $17.83 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.05 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.47 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $6.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadel Nammour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.